Ironwood Non Current Liabilities Total from 2010 to 2024
IRWD Stock | USD 8.12 0.18 2.17% |
Non Current Liabilities Total | First Reported 2008-12-31 | Previous Quarter 569.2 M | Current Value 541.3 M | Quarterly Volatility 191.4 M |
Check Ironwood Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ironwood main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 19.9 M or Total Revenue of 231.7 M, as well as many exotic indicators such as Price To Sales Ratio of 3.82, Dividend Yield of 0.0 or Days Sales Outstanding of 142. Ironwood financial statements analysis is a perfect complement when working with Ironwood Pharmaceuticals Valuation or Volatility modules.
Ironwood | Non Current Liabilities Total |
Latest Ironwood Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Ironwood Pharmaceuticals over the last few years. It is Ironwood Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ironwood Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
Timeline |
Ironwood Non Current Liabilities Total Regression Statistics
Arithmetic Mean | 352,288,593 | |
Geometric Mean | 274,504,482 | |
Coefficient Of Variation | 48.48 | |
Mean Deviation | 137,076,129 | |
Median | 408,897,000 | |
Standard Deviation | 170,795,678 | |
Sample Variance | 29171.2T | |
Range | 521.1M | |
R-Value | 0.65 | |
Mean Square Error | 18126.9T | |
R-Squared | 0.42 | |
Significance | 0.01 | |
Slope | 24,838,562 | |
Total Sum of Squares | 408396.3T |
Ironwood Non Current Liabilities Total History
About Ironwood Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Ironwood Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Ironwood Pharmaceuticals investors use historical funamental indicators, such as Ironwood Pharmaceuticals's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Ironwood Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Ironwood Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ironwood Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Ironwood Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Ironwood Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Non Current Liabilities Total | 541.3 M | 370.6 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Ironwood Pharmaceuticals Correlation against competitors. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.45) | Revenue Per Share 2.848 | Quarterly Revenue Growth 0.097 | Return On Assets 0.1339 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.